Showing 4291-4300 of 5303 results for "".
- Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Diseasehttps://practicaldermatology.com/news/novartis-new-data-show-cosentyx-has-durable-response-across-psoriatic-disease/2460068/A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, random
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en
- Data Show 2-Year Complete Response with AbbVie's Skyrizi: WCDhttps://practicaldermatology.com/news/data-show-2-year-complete-response-with-abbvies-skyrizi-wcd/2460064/New results presented by AbbVie show that a significant number of patients treated with Skyrizi™ (risankizumab) experienced complete skin clearance at week 94. These two-year results (up to 104 weeks) from the Phase 3 IMMhance study, evaluating the efficacy and safety of SKYRIZI in adu
- Burt's Bees Data at WCD Highlights Power of Naturalshttps://practicaldermatology.com/news/burts-bees-data-at-wcd-highlights-power-of-naturals/2460062/New research from Burt's Bees supports findings related to the skin's composition and the role of nature-based regimens to protect the skin against common environmental stressors. The studies will be presented at the 24th World Congress of Dermatology (WCD) Meeting in Milan
- Registration Open for Skin of Color Update Meetinghttps://practicaldermatology.com/news/registration-open-for-skin-of-color-update-meeting/2460060/The medical education event focused on the dermatologic treatment of skin of color has a new name. Skin of Color Update, previously the Skin of Color Seminar Series, provides dermatologists with evidence-based research and practical pearls in treating skin of color, including patients with multir
- Study: Indoor Tanning Addiction May Be Abetted by Genetic and Psychiatric Factorshttps://practicaldermatology.com/news/study-indoor-tanning-addiction-may-be-abetted-by-genetic-and-psychiatric-factors/2460059/A combination of elevated symptoms of depression along with modifications in a gene responsible for dopamine activity appear to influence an addiction to indoor tanning in young, white non-Hispanic women, a new study suggests. The findings appear in the Annals of Behaviora
- Revance Therapeutics Welcomes Jill Beraud to Board of Directorshttps://practicaldermatology.com/news/revance-therapeutics-welcomes-jill-beraud-to-board-of-directors/2460053/Jill Beraud is now a member of Revance Therapeutics, Inc.'s Board of Directors. Ms. Beraud brings more than 25 years’ experience building luxury, fashion, beauty, and consumer brands. Ms. Beraud will also chair a newly-formed Revance Brand
- Sciton Promotes Two Leadershttps://practicaldermatology.com/news/sciton-promotes-two-leaders/2460050/Bryant Wong is the new Vice President of Finance at Sciton and Emma Haaland is the new Global Director of Customer Service. Mr. Wong spent two years as the leader of the finance department at Sciton. He worked for nearly 12 years with PricewaterhouseCoopers and Deloitte C
- Positive 90-Day Results from CONFORM Study: Recros Medicahttps://practicaldermatology.com/news/positive-90-day-results-from-conform-study-recros-medica/2460042/Ninety-day results from the CONFORM study assessing the efficacy, safety, and patient satisfaction of the Rotational Fractional Resection (RFR) procedure for submental contouring are promising. RFR is a novel, proprietary alternative to traditional approaches to treat skin laxity developed by
- FDA Approves Sorilux for Adolescent Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-sorilux-for-adolescent-plaque-psoriasis/2460039/The FDA has approved Mayne Pharma Group Limited's Sorilux (calcipotriene) Foam, 0.005% in adolescents 12 years and older. The FDA approved Sorilux in 2010 based on evidence from two eight-week placebo controlled clinical trials in patients with mild to moderate plaque psoriasis of t